We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+60.43%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$242M
AUM Growth
+$20.3M
Cap. Flow
-$14.2M
Cap. Flow %
-5.88%
Top 10 Hldgs %
67.89%
Holding
53
New
6
Increased
20
Reduced
10
Closed
11
Avg Time Held
6.6 quarters
Top 10 Avg Time Held
6.2 quarters
Top 20 Avg Time Held
5.7 quarters

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.33M
2
TELA icon
TELA Bio
TELA
+$3.26M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.47M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.86M
5
LRMR icon
Larimar Therapeutics
LRMR
+$1.83M

Top Sells

Rank Stock Value
1
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.89M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$5.58M
3
INBX icon
Inhibrx, Inc. Common Stock
INBX
+$5.36M
4
MASS icon
908 Devices
MASS
+$3.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.09B
$40.4M 16.67%
3,343,817
+11,085
+0.3% +$89.9K
2018 Q3
16 quarters
OCUL icon
2
Ocular Therapeutix
OCUL
$1.66B
$26.8M 11.08%
6,465,000
+490,200
+8% +$2.47M
2019 Q1
14 quarters
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$6.18B
$19.8M 8.2%
810,000
+448,000
+124% +$8.33M
2022 Q2
1 quarter
TELA icon
4
TELA Bio
TELA
$48.8M
$17.4M 7.17%
2,036,551
+393,184
+24% +$3.26M
2019 Q4
11 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$13.2M 5.45%
671,300
– –
2021 Q1
6 quarters
CYTK icon
6
Cytokinetics
CYTK
$8.73B
$12.7M 5.26%
263,000
-39,500
-13% -$1.9M
2020 Q2
9 quarters
KROS icon
7
Keros Therapeutics
KROS
$230M
$12.1M 4.99%
321,300
+45,300
+16% +$1.57M
2021 Q1
6 quarters
TARA icon
8
Protara Therapeutics
TARA
$164M
$7.99M 3.3%
2,708,067
+23,900
+0.9% +$81K
2019 Q3
12 quarters
CDXS icon
9
Codexis
CDXS
$154M
$7M 2.89%
1,155,000
-133,450
-10% -$1.07M
2014 Q1
34 quarters
TCON
10
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$7M 2.89%
209,500
+3,234
+2% +$123K
2020 Q3
8 quarters
CUTR icon
11
DELISTED
Cutera, Inc.
CUTR
$6.74M 2.78%
147,700
– –
2022 Q2
1 quarter
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.18B
$6.25M 2.58%
635,000
+183,600
+41% +$1.86M
2022 Q1
2 quarters
MRSN icon
13
DELISTED
Mersana Therapeutics
MRSN
$6.09M 2.51%
36,012
-5,868
-14% -$954K
2022 Q1
2 quarters
LRMR icon
14
Larimar Therapeutics
LRMR
$263M
$5.32M 2.2%
1,661,784
+728,970
+78% +$1.83M
2021 Q2
5 quarters
ETON icon
15
Eton Pharmaceutcials
ETON
$1.58B
$5.29M 2.19%
2,521,000
+58,500
+2% +$146K
2018 Q4
15 quarters
INBX icon
16
DELISTED
Inhibrx, Inc. Common Stock
INBX
$5.25M 2.17%
292,700
-297,300
-50% -$5.36M
2022 Q2
1 quarter
MRUS icon
17
DELISTED
Merus
MRUS
$5.07M 2.09%
253,200
-84,800
-25% -$2.02M
2021 Q3
4 quarters
PCVX icon
18
Vaxcyte
PCVX
$11B
$4.56M 1.88%
190,000
– –
2020 Q3
8 quarters
XOMA icon
19
DELISTED
Xoma
XOMA
$4.44M 1.83%
248,000
-15,050
-6% -$310K
2017 Q1
22 quarters
URGN icon
20
UroGen Pharma
URGN
$1.87B
$3.31M 1.37%
397,500
+158,830
+67% +$1.31M
2022 Q2
1 quarter
LQDA icon
21
Liquidia Corp
LQDA
$2.48B
$3.06M 1.27%
563,500
+42,000
+8% +$236K
2021 Q4
3 quarters
FDMT icon
22
4D Molecular Therapeutics
FDMT
$718M
$2.82M 1.16%
350,700
+25,700
+8% +$233K
2021 Q4
3 quarters
STXS icon
23
Stereotaxis
STXS
$114M
$2.8M 1.16%
1,556,800
-543,171
-26% -$1.16M
2019 Q3
12 quarters
FBIO icon
24
Fortress Biotech
FBIO
$70.4M
$2.58M 1.07%
199,933
-16,546
-8% -$248K
2020 Q2
9 quarters
PRQR icon
25
ProQR Therapeutics
PRQR
$229M
$2.32M 0.96%
3,115,000
+375,000
+14% +$301K
2021 Q1
6 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2022 Portfolio in Review

As of Q3 2022, Opaleye Management held 53 positions worth $242M, up 9.1% from $222M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Opaleye Management withdrew a net $14.2M in Q3 2022, closing 11 positions and reducing 10 holdings. Its most notable exit was Kiniksa Pharmaceuticals, an estimated $7.89M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Astria Therapeutics worth $1.21M.

  • Opaleye Management's largest Q3 2022 buy was Astria Therapeutics: 133,500 shares worth $1.21M.
  • Opaleye Management added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $8.33M increase.
  • Opaleye Management's biggest Q3 2022 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.36M.
  • Opaleye Management fully exited Kiniksa Pharmaceuticals in Q3 2022, selling an estimated $7.89M.
  • Opaleye Management's ten largest holdings make up 68% of its $242M portfolio in Q3 2022.
  • Opaleye Management opened 6 new positions and closed 11 in Q3 2022.
  • Opaleye Management's portfolio value rose 9.1% quarter-over-quarter to $242M.

Based on Opaleye Management's 13F filing for Q3 2022, filed 14 Nov 2022.